{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"15"}],"units":"Participants"}],"description":"Number of participants achieving confirmed OR based on irRECIST in Part 1. OR = irCR + irPR. Overall immune related complete response (irCR) was defined as complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also must have a reduction in short axis to \\<10 mm. Overall immune related partial response (irPR) was defined as sum of the diameters (longest for non nodal lesions, shortest for nodal lesions) of target and new measurable lesions decreases \\>=30%.","groups":[{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"OG000","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"OG001","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"OG002","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"OG003","title":"Part 1: PF-06801591 10 mg/kg (IV)"},{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG004","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population included all the randomized participants who received at least 1 dose of study medication, had measurable disease baseline assessment (within 28 days prior to study entry) and at least 1 post baseline assessment or disease progression, global deterioration of health status, or death.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment in Part 1 (maximum of 1606 days)","title":"Number of Participants Achieving Objective Response (OR) Based on irRECIST - Part 1","type":"SECONDARY","unitOfMeasure":"Participants"}